Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Protriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS, Clinical Worsening and Suicide Risk; PRECAUTIONS, Information for Patients; and PRECAUTIONS, Pediatric Use)
Protriptyline hydrochloride is an antidepressant agent.
Protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients.
Media Articles Related to Vivactil (Protriptyline)
Postpartum depression least severe form of depression in mothers
Source: Depression News From Medical News Today [2016.06.17]
Time frame when pregnant woman first develops depression determines severity, treatment of it.
Untreated Depression in Pregnancy Linked to Low Birth Weight
Source: Medscape Psychiatry & Mental Health Headlines [2016.06.16]
A new analysis also found increased risk for preterm births among expectant mothers with untreated depression.
Medscape Medical News
Community-based programme improves depression in chronic pain patients
Source: Depression News From Medical News Today [2016.06.15]
A community-based pain management programme for patients with chronic musculoskeletal pain has improved depression and social integration, according to a study led by Queen Mary University of...
Major depression: Most antidepressants ineffective for children, teens
Source: Depression News From Medical News Today [2016.06.09]
A review in The Lancet finds that most antidepressants offer no benefit for children and adolescents with major depression, and they may even cause harm.
Depression: Tips for Exercise, Diet and Stress Reduction
Source: MedicineNet Depression Specialty [2016.06.09]
Title: Depression: Tips for Exercise, Diet and Stress Reduction
Created: 6/1/2009 12:00:00 AM
Last Editorial Review: 6/9/2016 12:00:00 AM
Published Studies Related to Vivactil (Protriptyline)
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.
Protriptyline, chronic tension-type headaches, and weight loss in women. [1997.07]
Twenty-five women with chronic tension-type headaches were treated with protriptyline for 3 months, with attention paid to days of monthly headaches before and while taking the medication, as well as change in weight and side effects. One patient stopped the medication because of side effects and 2 did not return for follow-up, yielding 22 patients...
Clinical Trials Related to Vivactil (Protriptyline)
Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets
under fasted conditions
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
Page last updated: 2016-06-17